Key facts
- Notable investors include Empower Investment, Luzhou Puquan Private Equity Investment Fund Management.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Sichuan Nuohong Huikang Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Sichuan Nuohong Huikang Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sichuan Nuohong Huikang Biotechnology
Operator of biopharmaceutical reagents and cell culture media company intended for scientific research, clinical applications, and industrial bioprocessing. The company integrates standardized and customized media formulations, stem cell-specific solutions, and advanced production technologies with rigorous quality control and international compliance, enabling global biotechnology and life sciences markets to conduct high-precision cell biology research, optimize therapeutic development, and ensure consistent experimental outcomes through reliable, tailored reagent systems and expert technical support.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2023
- Website
- sperikon.com/
- Ownership
- Privately Held (backing)
Sichuan Nuohong Huikang Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sichuan Nuohong Huikang Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sichuan Nuohong Huikang Biotechnology in its N-PORT filings yet. We sweep new filings monthly.